Literature DB >> 31515708

Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia.

Machiko Fujioka1,2, Hidehiro Itonaga3, Takeharu Kato4, Yasuhito Nannya5, Miki Hashimoto2, Sachie Kasai6, Eo Toriyama6, Rena Kamijo6, Masataka Taguchi1, Hiroaki Taniguchi6, Shinya Sato1, Sunao Atogami7, Yoshitaka Imaizumi2, Tomoko Hata2, Yukiyoshi Moriuchi6, Seishi Ogawa5, Yasushi Miyazaki1,2.   

Abstract

A 68-year-old male was diagnosed with acute promyelocytic leukemia (APL). A G-banding chromosomal analysis revealed the co-existence of two clones: one with del(20q) and t(15;17)(q22;q12) and another with del(20q) alone. During the remission of APL following treatment with all-trans-retinoic acid, del(20q) was persistently identified, indicating a diagnosis of cytogenetic abnormalities of undetermined significance (CCAUS) with isolated del(20q). Bicytopenia developed 48 months after the remission of APL. The presence of isolated del(20q) was detected in the G-banding analysis, whereas morphological dysplasia of hematopoietic cells was not confirmed. This case showed indolent progression from CCAUS after the remission of APL to clonal cytopenia of undetermined significance (CCUS). CCUS with isolated del(20q) persisted for 24 months without any finding of hematological malignancies. At the most recent follow-up, targeted capture sequencing showed the U2AF1 S34F mutation. Considerable attention needs to be paid in follow-ups for CCAUS with del(20q) after the treatment of leukemia.

Entities:  

Keywords:  Acute promyelocytic leukemia; All-trans-retinoic acid; Clonal hematopoiesis; Cytopenia of undetermined significance (CCUS); del(20q)

Mesh:

Substances:

Year:  2019        PMID: 31515708     DOI: 10.1007/s12185-019-02731-w

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  19 in total

Review 1.  How I investigate Clonal cytogenetic abnormalities of undetermined significance.

Authors:  G Tang; L J Medeiros; S A Wang
Journal:  Int J Lab Hematol       Date:  2018-04-06       Impact factor: 2.877

2.  Clonal haemopoiesis in normal elderly women: implications for the myeloproliferative disorders and myelodysplastic syndromes.

Authors:  K M Champion; J G Gilbert; F A Asimakopoulos; S Hinshelwood; A R Green
Journal:  Br J Haematol       Date:  1997-06       Impact factor: 6.998

Review 3.  CHIP, ICUS, CCUS and other four-letter words.

Authors:  R Bejar
Journal:  Leukemia       Date:  2017-06-08       Impact factor: 11.528

4.  Age-related clonal hematopoiesis associated with adverse outcomes.

Authors:  Siddhartha Jaiswal; Pierre Fontanillas; Jason Flannick; Alisa Manning; Peter V Grauman; Brenton G Mar; R Coleman Lindsley; Craig H Mermel; Noel Burtt; Alejandro Chavez; John M Higgins; Vladislav Moltchanov; Frank C Kuo; Michael J Kluk; Brian Henderson; Leena Kinnunen; Heikki A Koistinen; Claes Ladenvall; Gad Getz; Adolfo Correa; Benjamin F Banahan; Stacey Gabriel; Sekar Kathiresan; Heather M Stringham; Mark I McCarthy; Michael Boehnke; Jaakko Tuomilehto; Christopher Haiman; Leif Groop; Gil Atzmon; James G Wilson; Donna Neuberg; David Altshuler; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2014-11-26       Impact factor: 91.245

Review 5.  Epigenetic dysregulation of hematopoietic stem cells and preleukemic state.

Authors:  Hiroyoshi Kunimoto; Hideaki Nakajima
Journal:  Int J Hematol       Date:  2017-05-29       Impact factor: 2.490

Review 6.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Authors:  Adam S Sperling; Christopher J Gibson; Benjamin L Ebert
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

7.  Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation.

Authors:  Raavi Gupta; Chad P Soupir; Vandita Johari; Robert P Hasserjian
Journal:  Br J Haematol       Date:  2007-08-30       Impact factor: 6.998

8.  Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.

Authors:  Gary J Schiller; James Slack; John D Hainsworth; James Mason; Mansoor Saleh; David Rizzieri; Dan Douer; Alan F List
Journal:  J Clin Oncol       Date:  2006-05-01       Impact factor: 44.544

9.  Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.

Authors:  Jorge Medina; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Mary Beth Rios; Kimberly Hayes; Jorge Cortes
Journal:  Cancer       Date:  2003-11-01       Impact factor: 6.860

10.  Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.

Authors:  Koichi Takahashi; Feng Wang; Hagop Kantarjian; Denaha Doss; Kanhav Khanna; Erika Thompson; Li Zhao; Keyur Patel; Sattva Neelapu; Curtis Gumbs; Carlos Bueso-Ramos; Courtney D DiNardo; Simona Colla; Farhad Ravandi; Jianhua Zhang; Xuelin Huang; Xifeng Wu; Felipe Samaniego; Guillermo Garcia-Manero; P Andrew Futreal
Journal:  Lancet Oncol       Date:  2016-12-03       Impact factor: 41.316

View more
  1 in total

1.  Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.

Authors:  Miki Hashimoto; Hidehiro Itonaga; Yasuhito Nannya; Hirokazu Taniguchi; Yuichi Fukuda; Takafumi Furumoto; Machiko Fujioka; Sachie Kasai; Masataka Taguchi; Hiroaki Taniguchi; Shinya Sato; Yasushi Sawayama; Sunao Atogami; Keisuke Iwasaki; Tomoko Hata; Hiroshi Soda; Yukiyoshi Moriuchi; Koh Nakata; Seishi Ogawa; Yasushi Miyazaki
Journal:  Intern Med       Date:  2019-12-26       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.